Dose-dense weekly (8 weeks) vs. sequential (24 weeks) neoadjuvant chemotherapy with adriamycin/cyclophosphamide and docetaxel in operable breast cancer (T2-3, N0-2, M0)-interim analysis of the Geparduo trial-.
BREAST CANCER RESEARCH AND TREATMENT（2001）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要